肌萎缩侧索硬化临床特征及预后因素研究进展

doi:10.11958/20230475

天津医药 ›› 2023, Vol. 51 ›› Issue (7): 694-696.doi: 10.11958/20230475

所属专题：专题研究

• 专题研究·肌萎缩侧索硬化 • 上一篇下一篇

肌萎缩侧索硬化临床特征及预后因素研究进展

赵小泉(), 卢祖能()

武汉大学人民医院神经内科（邮编430060）

收稿日期:2023-04-03 修回日期:2023-04-26 出版日期:2023-07-15 发布日期:2023-06-20
通讯作者: ^△卢祖能 E-mail:lzn196480@126.com
作者简介:赵小泉（1998），女，硕士在读，主要从事神经肌肉疾病方面研究。E-mail：2834855143@qq.com

Advances in clinical characteristics and prognostic factors of amyotrophic lateral sclerosis

ZHAO Xiaoquan(), LU Zuneng()

Department of Neurology, Renmin Hospital of Wuhan University, Wuhan 430060, China

Received:2023-04-03 Revised:2023-04-26 Published:2023-07-15 Online:2023-06-20
Contact: ^△LU Zuneng E-mail:lzn196480@126.com

赵小泉, 卢祖能. 肌萎缩侧索硬化临床特征及预后因素研究进展[J]. 天津医药, 2023, 51(7): 694-696.

ZHAO Xiaoquan, LU Zuneng. Advances in clinical characteristics and prognostic factors of amyotrophic lateral sclerosis[J]. Tianjin Medical Journal, 2023, 51(7): 694-696.

摘要/Abstract

摘要：

肌萎缩侧索硬化（ALS）是一种具有明显临床异质性的神经变性疾病，从确诊到死亡或严重残疾的时间进程极其多变。ALS的异质性在很大程度上阻碍了准确的终点结局预测和新型治疗方法的开发。ALS预后因素的进一步识别将有助于构建良好的生存预测模型，准确预测生存时间，进而推动ALS治疗的发展。

关键词: 肌萎缩侧索硬化, 预后, 预测模型

Abstract:

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with marked clinical heterogeneity, with an extremely variable time course from diagnosis to death or severe disability. The heterogeneity of ALS hinders the accurate prediction of endpoints and the development of novel therapies. Further identification of ALS prognostic factors will help to build a good survival prediction model, accurately predict survival time, and promote the development of ALS treatment.

Key words: amyotrophic lateral sclerosis, prognosis, prediction model

中图分类号:

R746.4

参考文献 34

[1]	KIERNAN M C, VUCIC S, TALBOT K, et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis[J]. Nat Rev Neurol, 2021, 17(2):104-118. doi:10.1038/s41582-020-00434-z.
[2]	BAUCKNEHT M, LAI R, MICELI A, et al. Spinal cord hypermetabolism extends to skeletal muscle in amyotrophic lateral sclerosis:a computational approach to [18F]-fluorodeoxyglucose PET/CT images[J]. EJNMMI Res, 2020, 10(1):23. doi:10.1186/s13550-020-0607-5.
[3]	GAO M, LIU N, LI X M, et al. Epidemiology and factors predicting survival of amyotrophic lateral sclerosis in a large Chinese cohort[J]. Chin Med J(Engl), 2021, 134(18):2231-2236. doi:10.1097/CM9.0000000000001679.
[4]	SUN Q, HUO Y, BAI J, et al. Characteristics of late-onset amyotrophic lateral sclerosis in a Chinese cohort[J]. Neurodegener Dis, 2021, 21(1/2):24-29. doi:10.1159/000519002.
[5]	HUANG S, ZHENG M, LIN J, et al. Natural history and remarkable psychiatric state of late-onset amyotrophic lateral sclerosis in China[J]. Acta Neurol Scand, 2022, 146(1):24-33. doi:10.1111/ane.13598.
[6]	LI J Y, SUN X H, CAI Z Y, et al. Correlation of weight and body composition with disease progression rate in patients with amyotrophic lateral sclerosis[J]. Sci Rep, 2022, 12(1):13292. doi:10.1038/s41598-022-16229-9.
[7]	SUN Q H, LI Y R, LAN W J, et al. Prognostic value of time to generalization in 71 Chinese patients with sporadic amyotrophic lateral sclerosis[J]. Chin Med J(Engl), 2019, 132(9):1023-1027. doi: 10.1097/CM9.0000000000000200.
[8]	HE Z, SUN B, FENG F, et al. Time of symptoms beyond the bulbar region predicts survival in bulbar onset amyotrophic lateral sclerosis[J]. Neurol Sci, 2022, 43(3):1817-1822. doi:10.1007/s10072-021-05556-w.
[9]	RICHARDS D, MORREN J A, PIORO E P. Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis[J]. J Neurol Sci, 2020, 417:117054. doi:10.1016/j.jns.2020.117054.
[10]	SUN C, FOURNIER C N, YE S, et al. Chinese validation of the Rasch-built overall amyotrophic lateral sclerosis disability scale[J]. Eur J Neurol, 2021, 28(6):1876-1883. doi:10.1111/ene.14811.
[11]	FOURNIER C N, BEDLACK R, QUINN C, et al. Development and validation of the Rasch-built overall amyotrophic lateral sclerosis disability scale(ROADS)[J]. JAMA Neurol, 2020, 77(4):480-488. doi:10.1001/jamaneurol.2019.4490.
[12]	PINTO S, de CARVALHO M. SVC is a marker of respiratory decline function, similar to FVC, in patients with ALS[J]. Front Neurol, 2019, 10:109. doi:10.3389/fneur.2019.00109.
[13]	ENACHE I, PISTEA C, FLEURY M, et al. Ability of pulmonary function decline to predict death in amyotrophic lateral sclerosis patients[J]. Amyotroph Lateral Scler Frontotemporal Degener, 2017, 18(7/8):511-518. doi:10.1080/21678421.2017.1353097.
[14]	HUANG X, DU C, YANG Q, et al. Comparison of slow and forced vital capacity on ability to evaluate respiratory function in bulbar-involved amyotrophic lateral sclerosis[J]. Front Neurol, 2022, 13:938256. doi:10.3389/fneur.2022.938256.
[15]	HUYNH W, AHMED R, MAHONEY C J, et al. The impact of cognitive and behavioral impairment in amyotrophic lateral sclerosis[J]. Expert Rev Neurother, 2020, 20(3):281-293. doi:10.1080/14737175.2020.1727740.
[16]	XU Z, ALRUWAILI A, HENDERSON R D, et al. Screening for cognitive and behavioural impairment in amyotrophic lateral sclerosis:Frequency of abnormality and effect on survival[J]. J Neurol Sci, 2017, 376:16-23. doi:10.1016/j.jns.2017.02.061.
[17]	MURDOCK B J, ZHOU T, KASHLAN S R, et al. Correlation of peripheral immunity with rapid amyotrophic lateral sclerosis progression[J]. JAMA Neurol, 2017, 74(12):1446-1454. doi:10.1001/jamaneurol.2017.2255.
[18]	CUI C, INGRE C, YIN L, et al. Correlation between leukocyte phenotypes and prognosis of amyotrophic lateral sclerosis[J]. Elife, 2022, 11:e74065. doi:10.7554/eLife.74065.
[19]	INGRE C, CHEN L, ZHAN Y, et al. Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis[J]. Neurology, 2020, 94(17): e1835-e1844. doi:10.1212/WNL.0000000000009322.
[20]	HOLDOM C J, JANSE V M M, VAN EIJK R, et al. Venous creatinine as a biomarker for loss of fat-free mass and disease progression in patients with amyotrophic lateral sclerosis[J]. Eur J Neurol, 2021, 28(11):3615-3625. doi:10.1111/ene.15003.
[21]	GUO Q F, HU W, XU L Q, et al. Decreased serum creatinine levels predict short survival in amyotrophic lateral sclerosis[J]. Ann Clin Transl Neurol, 2021, 8(2):448-455. doi:10.1002/acn3.51299.
[22]	CHENG Y, CHEN Y, SHANG H. Aberrations of biochemical indicators in amyotrophic lateral sclerosis:a systematic review and meta-analysis[J]. Transl Neurodegener, 2021, 10(1):3. doi:10.1186/s40035-020-00228-9.
[23]	de CARVALHO M, DENGLER R, EISEN A, et al. Electrodiagnostic criteria for diagnosis of ALS[J]. Clin Neurophysiol, 2008, 119(3):497-503. doi:10.1016/j.clinph.2007.09.143.
[24]	SATO M, NAKAMURA T, NAGASHIMA K, et al. Prolonged distal latency of the median motor nerve is associated with poor prognosis in amyotrophic lateral sclerosis[J]. Neurol Res, 2021, 43(3):191-198. doi:10.1080/01616412.2020.1834291.
[25]	IMAI E, NAKAMURA T, ATSUTA N, et al. A nerve conduction study predicts the prognosis of sporadic amyotrophic lateral sclerosis[J]. J Neurol, 2020, 267(9):2524-2532. doi:10.1007/s00415-020-09858-5.
[26]	FILECCIA E, De PASQUA S, RIZZO G, et al. Denervation findings on EMG in amyotrophic lateral sclerosis and correlation with prognostic milestones:Data from a retrospective study[J]. Clin Neurophysiol, 2020, 131(8):2017-2022. doi:10.1016/j.clinph.2020.04.161.
[27]	VACCHIANO V, DI STASI V, RIZZO G, et al. Prognostic value of EMG genioglossus involvement in amyotrophic lateral sclerosis[J]. Clin Neurophysiol, 2021, 132(10):2416-2421. doi:10.1016/j.clinph.2021.07.011.
[28]	COLOMBO E, DORETTI A, SCHEVEGER F, et al. Correlation between clinical phenotype and electromyographic parameters in amyotrophic lateral sclerosis[J]. J Neurol, 2023, 270(1):511-518. doi:10.1007/s00415-022-11404-4.
[29]	FERRARO P M, CABONA C, MEO G, et al. Age at symptom onset influences cortical thinning distribution and survival in amyotrophic lateral sclerosis[J]. Neuroradiology, 2021, 63(9):1481-1487. doi:10.1007/s00234-021-02681-3.
[30]	MILELLA G, INTRONA A, GHIRELLI A, et al. Medulla oblongata volume as a promising predictor of survival in amyotrophic lateral sclerosis[J]. Neuroimage Clin, 2022, 34:103015. doi:10.1016/j.nicl.2022.103015.
[31]	RIZZO G, MARLIANI A F, BATTAGLIA S, et al. Diagnostic and prognostic value of conventional brain MRI in the clinical work-up of patients with amyotrophic lateral sclerosis[J]. J Clin Med, 2020, 9(8):2538. doi:10.3390/jcm9082538.
[32]	TAVAZZI E, DABERDAKU S, ZANDONA A, et al. Predicting functional impairment trajectories in amyotrophic lateral sclerosis:a probabilistic, multifactorial model of disease progression[J]. J Neurol, 2022, 269(7):3858-3878. doi:10.1007/s00415-022-11022-0.
[33]	ACKRIVO J, HANSEN-FLASCHEN J, WILEYTO E P, et al. Development of a prognostic model of respiratory insufficiency or death in amyotrophic lateral sclerosis[J]. Eur Respir J, 2019, 53(4):1802237. doi:10.1183/13993003.02237-2018.
[34]	GROLLEMUND V, CHAT G L, SECCHI-BUHOUR M S, et al. Development and validation of a 1-year survival prognosis estimation model for amyotrophic lateral sclerosis using manifold learning algorithm UMAP[J]. Sci Rep, 2020, 10(1):13378. doi:10.1038/s41598-020-70125-8.

肌萎缩侧索硬化临床特征及预后因素研究进展

Advances in clinical characteristics and prognostic factors of amyotrophic lateral sclerosis

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

参考文献 34

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨敏, 潘艳莎, 张长玲, 陈红英, 郭渠莲, 刘文君. 儿童急性淋巴细胞白血病基线数据及早期治疗反应与预后的相关性[J]. 天津医药, 2024, 52(9): 954-958.
[2]	王新波, 罗冰清, 石玉宝, 张也, 席江伟. 结直肠癌组织LncRNA LINC00342和miR-203a-3p表达及与预后的关系[J]. 天津医药, 2024, 52(9): 971-976.
[3]	戴瑶, 方向, 黄康, 冯洁, 刘敏, 伍松柏. HAT疗法治疗脓毒症休克的临床疗效观察[J]. 天津医药, 2024, 52(8): 825-829.
[4]	林峰, 陈铃雄, 刘羽, 张旭明, 尹志达, 林坛辉, 刘尊荣. 紫杉醇涂层球囊治疗2型糖尿病膝下动脉严重病变患者发生远期再狭窄预测模型的构建[J]. 天津医药, 2024, 52(8): 830-834.
[5]	张锡友, 郭一丹, 张春霞, 周晓玲, 贾萌, 石志华, 罗洋. 老年维持性血液透析患者高钾血症与不良预后事件相关性的临床研究[J]. 天津医药, 2024, 52(8): 840-844.
[6]	满祎, 许娅, 何先成, 宋少锋, 刘爱国. 三阴性乳腺癌EGFR、Ki-67、P53及CTC表达与预后的关系研究[J]. 天津医药, 2024, 52(8): 862-867.
[7]	历丽, 曹树明, 杨仲平, 胡若梅. 鱼胶原低聚肽对急诊复杂手外伤手术患者预后的影响[J]. 天津医药, 2024, 52(8): 868-871.
[8]	罗宴冉, 史晓飞, 韩磊, 张贝, 文路遥. 皮肌炎自身抗体在间质性肺病中的研究进展[J]. 天津医药, 2024, 52(7): 704-708.
[9]	王娴, 刘霞明, 陈曼玉, 赵君, 王立东. 基于机器学习对2型糖尿病肾病预测模型的构建及验证[J]. 天津医药, 2024, 52(7): 775-780.
[10]	薛晶, 元小冬, 邢爱君, 王连辉, 马倩, 符永山, 张萍淑. 急性缺血性脑卒中患者睡眠-觉醒生物节律变化与预后的关系研究[J]. 天津医药, 2024, 52(6): 614-619.
[11]	叶朝阳, 马建中, 李后俊, 魏鲲鹏. 急性胰腺炎患者外周血TLR4、IL-1β、NLR水平与疾病进展和预后的关系[J]. 天津医药, 2024, 52(6): 648-652.
[12]	王灵, 龙登炎. 重症监护病房获得性衰弱风险预测模型的构建[J]. 天津医药, 2024, 52(5): 486-489.
[13]	吕梦娜, 李建斌, 吴锐. 自身炎症性疾病患者合并COVID-19严重程度的早期预测指标探讨[J]. 天津医药, 2024, 52(5): 528-531.
[14]	吴纪昆, 徐榕笛, 许景涵, 王乐, 丛洪良. 6种常见模型评分对NSTEMI患者远期预后预测价值的验证和比较[J]. 天津医药, 2024, 52(5): 541-547.
[15]	王宁方, 赵崇山, 刘方, 赵鹏浩, 张东东, 蔡卓纹, 蔡芳芳. 多发性骨髓瘤患者淋巴细胞来源微泡的检测及其临床意义[J]. 天津医药, 2024, 52(4): 409-415.